Thalidomide in the treatment of relapsed and refractory myeloma.

被引：0
|
作者：
Rajkumar, SV [1 ]
Fonseca, R [1 ]
Dispenzieri, A [1 ]
Lacy, MQ [1 ]
Witzig, TE [1 ]
Lust, JA [1 ]
Kyle, RA [1 ]
Gertz, MA [1 ]
Greipp, PR [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1414
引用
收藏
页码：316A / 316A
页数：1
相关论文
共 50 条
  • [41] Bendamustine in combination with thalidomide and prednisone in patients with refractory or relapsed multiple myeloma. preliminary results of a phase I clinical trial
    Pönisch, W
    Rozanski, M
    Leiblein, S
    Goldschmidt, H
    Wegner, A
    Niederwieser, D
    ANNALS OF ONCOLOGY, 2005, 16 : 208 - 208
  • [42] Thalidomide-induced leukopenia in Japanese patients with refractory multiple myeloma.
    Murakami, Hirokazu
    Handa, Hiroshi
    Abe, Masahiro
    Iida, Shinsuke
    Ishii, Akihiro
    Ishikawa, Takayuki
    Ishida, Tadao
    Oota, Masatsugu
    Ozaki, Shuji
    Kosaka, Masaaki
    Sakai, Akira
    Sawamura, Morio
    Shimizu, Kazuaki
    Takagi, Toshiyuki
    Hata, Hiroyuki
    Fukuhara, Takashi
    Fujii, Hiroshi
    Miyata, Akira
    Wakayama, Toshio
    Takatsuki, Kiyoshi
    BLOOD, 2006, 108 (11) : 361B - 361B
  • [43] Single-agent Aredia for relapsed/refractory multiple myeloma.
    Berenson, JR
    Webb, IJ
    Anderson, K
    Schlossman, R
    Vescio, R
    Doss, D
    Goon, B
    Swift, R
    VonTeichert, J
    Kowalski, M
    Seaman, J
    BLOOD, 1999, 94 (10) : 307B - 307B
  • [44] Low-dose thalidomide in patients with advanced, refractory multiple myeloma.
    Chen, CI
    Adesanya, A
    Sutton, DM
    Brandwein, J
    Stewart, AK
    BLOOD, 1999, 94 (10) : 308B - 308B
  • [45] A phase II trial of Gleevec™ in patients with refractory/relapsed myeloma.
    Dispenzieri, A
    Witzig, TE
    Lacy, MQ
    Rajkumar, SV
    Geyer, SM
    Kimlinger, T
    Greipp, PR
    Fonseca, R
    Lust, JA
    Gertz, MA
    BLOOD, 2002, 100 (11) : 814A - 814A
  • [46] Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Mark, Tomer Martin
    Rodriguez, Melissa
    Shah, Manan
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Speaker, Stephanie
    Jayabalan, David
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] The lack of clinical efficacy of flavopiridol in patients with relapsed refractory myeloma.
    Dispenzieri, A
    Bible, KC
    Lacy, MQ
    Fitch, TR
    Geyer, SM
    Fenton, R
    Fonseca, R
    Getman, CR
    Ziesmer, SC
    Erlichman, C
    Gertz, MA
    BLOOD, 2004, 104 (11) : 943A - 943A
  • [48] Thalidomide in IgA multiple myeloma.
    Lim, SH
    Maclean, R
    BLOOD, 1998, 92 (10) : 279B - 279B
  • [49] Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeanenne Joy
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: Identification of prognostic factors
    Anagnostopoulos, A
    Gika, D
    Hamilos, G
    Zervas, K
    Zomas, A
    Pouli, A
    Zorzou, M
    Kastritis, E
    Anagnostopoulos, N
    Tassidou, A
    Anagnostou, D
    Dimopoulos, MA
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2275 - 2279
12345